TickerTalks
Browse all tickers →
TickerTalks›$CRSP
CRCRSP

CRISPR Therapeutics AG

$CRSP·$5.1B·Biotechnology·Healthcare
$48.57-5.5%YTD-7.9%1Y-2.6%
Mentions · last 7 days
2026-07-09: 21 posts2026-07-10: 41 posts2026-07-11: 13 posts2026-07-12: 15 posts2026-07-13: 37 posts2026-07-14: 26 posts2026-07-15: 24 posts181+5%
Price updated 6h ago·X counts updated 1d ago
CRCRSP
$CRSPCRISPR Therapeutics AG
$48.57-5.45%181 posts+5%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $CRSP, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersWinding up for a moveAI verdict · as of 2026-07-15

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

First commercially successful gene-editing therapy with CASGEVY — trading well below 2021 highs with Aug 3 print as the checkpoint.

CRISPR Therapeutics uses CRISPR/Cas9 gene-editing technology to develop transformative medicines. Its co-developed sickle cell / beta-thalassemia therapy CASGEVY (with Vertex) has become the first commercially approved gene-editing therapy — the specific validation of the platform.

Where the setup lands:

  • Revenue is minimal: Q1 revenue was $1M — CASGEVY commercial ramp is happening at Vertex, not CRSP directly (co-developed with royalty economics), so the reported revenue understates the underlying platform value.
  • The pipeline is broad: gene-editing candidates for cardiovascular, oncology, immunology, and rare disease — combined with the CASGEVY commercial precedent, this supports the equity's optionality-heavy valuation.
  • The tape reflects the multi-year drawdown: shares at 18% of 52-week range and roughly 77% below the 2021 $220 peak — meaning the market has essentially priced in continued burn without near-term breakthrough revenue, giving asymmetric setup if any pipeline milestone lands.

Aug 3 earnings decides direction: any commentary on CASGEVY commercial ramp acceleration combined with pipeline-milestone timing color would push shares toward $60, while another wide EPS miss combined with any competitive commentary on Chinese biotech gene-editing peers would confirm the current stall and keep shares in the $50-53 buy-range floor.

Agrees with X sentimentAgree with the split X read — CASGEVY as the first commercial gene-editing success plus ARKK's 5% weighting is the legitimate bull anchor, and the $220-to-$50 peak-to-current framing is the honest counter. The verdict lands with the coiling setup.

What to watch: Aug 3 earnings: CASGEVY commercial ramp commentary, pipeline milestone timing, and Chinese gene-editing competitive color. Another wide EPS miss with competitive commentary keeps shares in the $50-53 buy-range floor.

On the calendar: 2026-08-03 — Q2 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment⚠7 posts analyzed · as of 2026-07-15 · top-engagement diverged

CRISPR Therapeutics chatter is mixed. Bulls point to CRSP as the first gene-editing company to achieve commercial success with CASGEVY, and it's the third-largest holding in Cathie Wood's ARKK at 5%. Buy zone is set at $50-53. Bears note CRSP was a $220 stock in 2021 and is now $59 - 'if ever there was a time to take a risk on this dog it's now' but note continued clinical execution risk. In the gene-editing ranking CRSP is behind NTLA and BEAM (NTLA > BEAM > CRSP > PRME > EDIT). Sentiment is cautiously optimistic.

Read the AI verdict + X sentiment for $CRSP

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops CRISPR-Cas9 gene editing therapies, with Casgevy approved for sickle cell disease and beta-thalassemia.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $CRSP.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $CRSP

Partial — Develops CRISPR-Cas9 gene editing therapies, with Casgevy approved for sickle cell disease and beta-thalassemia; this segment overlaps with the GLP-1 pipeline bifurcation and ADA oral formulation competition but is not the dominant revenue driver.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.7%YTD
+44.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-8.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-21.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-134%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-8.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1218.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-30.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
-53.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 4, 2026$-1.28$-1.19-7.2%
Q4 2025Feb 12, 2026$-1.37$-1.15-19.1%
Q3 2025Nov 10, 2025$-1.17$-1.26+7.1%
Q2 2025Aug 4, 2025$-1.29$-1.47+12.2%
Next earningsMon, Aug 3·consensus EPS $-1.20

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$1.5M+68.6%-3346%-8933%$-1.28$-109.4M
Q4 FY25$864K-97.5%-6771%-17913%$-1.37$-93.1M
Q3 FY25$889K+47.7%-7177%-14855%$-1.17$-84.7M
Q2 FY25$892K+72.5%-5478%-14918%$-2.40$-114.0M

Forward consensus

5-year forecast · up to 15 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$37.2M$3.6M – $164.3M-$4.84-$5.82 – -$4.0315
FY27$137.7M$2.1M – $534.0M-$3.71-$5.09 – -$1.5615
FY28$537.3M$510.1M – $564.6M-$2.57-$9.86 – $10.4011
FY29$2.2B$47.0M – $8.1B$2.90-$0.79 – $12.945
FY30$5.5B$117.1M – $20.1B$15.40-$4.19 – $68.625

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.13%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-8.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-12.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellMay 29Naimish PatelChief Medical Officer3.8K sh$211KSellMar 23Samarth KulkarniCEO10.0K sh$469KSellMar 23James R. KasingerGeneral Counsel and Secretary3.2K sh$149KSellMar 23Raju PrasadCFO3.7K sh$173KSellMar 16Raju PrasadCFO9.9K sh$476KSellMar 16James R. KasingerGeneral Counsel and Secretary3.5K sh$166KSellMar 16Naimish PatelChief Medical Officer3.1K sh$152KSellMar 16Samarth KulkarniCEO10.3K sh$499KSellMar 11Samarth KulkarniCEO9.8K sh$517KSellMar 11James R. KasingerGeneral Counsel and Secretary2.8K sh$148K
1–10 of 14
+ 31 other (17 awards · 13 exempts · 1 gift) in window

See when $CRSP insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeJun 48-K — Item 5.02: Officer or director change · Item 5.03: Charter amendment · Item 5.07: Shareholder vote
AI summary

CRSP (CRSP) disclosed the results of its annual meeting of shareholders in an 8-K filing under Item 5.07. Shareholders voted on an equity incentive plan. All management-sponsored proposals were approved by majority shareholder vote. Annual meeting results are a routine disclosure that confirms shareholder ratification of the board's composition and compensation practices.

8-KMaterial agreementMar 168-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation · Item 3.02: Unregistered equity sale
+ 15 other (5 13Gs · 2 earnings 8-Ks · 2 proxys · 1 S-8) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Marketzacks.com·9h agoCRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on Itzacks.com·3d agoCRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Factszacks.com·6d ago3 Reasons to Buy CRISPR Therapeutics Stockfool.com·7d agoA New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeuticsfool.com·9d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPR

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$SLS$AURA$ATAI
Voices on X · top 6 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport